Marksans Pharma Ltd. — Interim / Quarterly Report 2021

Aug 11, 2021

BSE Limited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-l, Block-G, Bandra-Kurla Complex,. Bandra (East), Mumbai - 400051. Symbol: MARKSANS

Sub: Unaudited Financial Results for the quarter ended 30th June, 2021 and Limited Review Reports thereon.

In lerms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter ended 30th June, 2021 approved by the Board of Directors at its meeting held today i.e. 11th August, 2021 along with Limited Review Reports given by statutory auditor of the Company.

The meeting commenced at 11:00 a.m. and concluded at ''2.. \ l{) ~m.

You are requested to note the above in your records.

Yours faithfully, For Marksans Pharma Limited

. jPWMj&-

Harshavardhan Panigrahi Company Secretary

Marksans Pharma Ltd.;

11th Floor, "GRANDEUR" ^I Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400053 • Tel.: +91 224001 2000 • E-mail: info@marksanspharma.com www.marksanspharma.com

CHARTERED ACCOUNTANTS

901/902, Regent Chambers, Nariman Point, Mumbai – 400 021. T : +91 22 4343 9191 /+91 22 2283 2626 F : +91 22 2283 2727 bhutashah.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Marksans Pharma Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Marksans Pharma Limited

• 1. We have reviewed the accompanying statement of unaudited standalone financial results of Marksans Pharma Limited (the "Company") for the quarter ended 30 June, 2021 together with the notes thereon (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
• 1. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on the Statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Marksans Pharma Limited

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI Regulations, 2015 (as amended) to the extent applicable.

• 1. Attention is drawn to the fact that the figures for the 3 months ended 31 March, 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
• 1. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhuta Shah & Co LLP Chartered Accountants Firm's Registration Number: 101474W / W100100

Tejas Laliwala

Partner

CHARTERED ACCOUNTANTS

901/902, Regent Chambers, Nariman Point, Mumbai – 400 021. T : +91 22 4343 9191 /+91 22 2283 2626 F : +91 22 2283 2727 bhutashah.com

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of Marksans Pharma Limited Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Marksans Pharma Limited

• 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Marksans Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June, 2021 together with the notes thereon ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation").
• 1. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI Regulations, 2015 (as amended) to the extent applicable.

• Sr. No. Name of Company Nature of relationship 1 Marksans Pharma (UK) Limited Wholly Owned Subsidiary 2 Marksans Pharma Inc. Wholly Owned Subsidiary 3 Nova Pharmaceuticals Australasia Pty Ltd Subsidiary
• 1. The Statement includes the results of the following entities:

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of Marksans Pharma Limited

• 1. Attention is drawn to the fact that the figures for the 3 months ended 31 March, 2021 as reported in these consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
• 1. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
• 1. The Statement includes the interim financial information of unreviewed management accounts of one subsidiary, whose financial information reflects total revenue of Rs. 375.23 Mn., total net profit after tax of Rs. 18.84 Mn. and total comprehensive profit of Rs. 18.84 Mn. for the quarter ended 30 June 2021, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 18.84 Mn. for the quarter ended 30 June 2021, as considered in the consolidated unaudited financial results, in respect of this subsidiary, based on its interim financial information which have not been reviewed. According to the information and explanations given to us by the management, this interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For Bhuta Shah & Co LLP Chartered Accountants Firm's Registration Number: 101474W / W100100

Tejas Laliwala Partner Mumbai Membership Number: 127487

MARKSAN; IS PI -HARMA LIMITED

sai Telephone No.: 022-4001	Exte	MARKSAN; IS PI d,Oshi 2000, Fax No.:022-4004 2011, E-mail:	-HARMA LIMITED		info@marksanspharma.com
JNAUDITED FINANCIAL		TS FOR THE		ENDED 30 JUNE, 2021
		'STANDALONE				(in Million Except Share data)
		'QUARTER ENDED 30 June, 2021 34 March, 2024		YEAR ENDED.			YEAR ENDED, 34 March, 2024
Sr.No] PARTICULARS,	qunavorre) __ (auorTeD)			wuorren;	31 March, 2024] 30 June, 2024 unavorreD)
1 Revenue trom Operations							(avorreD)
	1.47221	1375.83		5,995.48	3,489.62		13,761.82
2 Other	139.40	119.08		311.56	58.84		65.94
3{Total Income (1+2) 4lEpenses	4,511.61	1,494.91		6,307.04	3,548.48		43,828.76
(Cost of Material Consumed Purchase of Stock-in-rade	787.63 25.63	744.90 99.99		2.91293 ] 460.66	1,133.43 63.27		4197.64 3,115.70
[Changes in inventories of finished goods, work-in-process Jand stock-in-trade	(6.64)	(45.96)		5.64	426.27		(1,362.78)
Employee benefits expense	140.40	156.74		546,39	490.45		1,973.23
Finance costs Depreciation and amortisation expense	6.30 4229	21.38 41.45		53.45 151.93	966 1471		79.88 361.51
Other expenses	214.02	152.37		932.84	602.83		2,461.95
'Total Expenses 5 Profit before tax (3-4)	1,269.83, 341.78	4,170.87 324.04		5,083.74 4,243.30	2,800.62 TAT.84		40,807.12 3,024.64
Tax expense:
(1) Current Year	56.24	76.58		281.88	130.94		686.94
(2) Earlier year	-	-		a	=		:
(3) Deferred tax 'Total Tax E:	(3.52) 52.72	10.58 87.16		(22.38) 259.48	(2.10)) 421.86		(30.68) 636.25
7)Profit for the period (5-6)	289.06	236.88		\$83.81	626.00		385.38
Other Comprehensive Income
tems that will not be rectassified to Profit or Loss income tax relating to above Items that will not be	(0.56)	(451)		(2.62)	(0.68)		262)
reclassified to Profit or Loss	O17	4.44		0.66	O47		0.66
tems that will be reclassified to profit or loss					53.57		6.64
8 Other Comprehensive Income 3 Total Comprehensive Income for the period (7+8)	(0.49) 288.57	(3.37) 233.51		(1.98) 981.85	53.08 679.08		468 2,390.06
10) Total Comprehensive Income attributable to-
[Non-Controling interests	-	Z		=	154		25.99
Owners of the Company 41 Paid up Equity Share Capital (Face Value 71 each)	288.57 40931	233.51 409.31		981.85 408.31	S71.54 409.31		2,364.07
(Other equity 42 Eamings Per Share of €1 each Basic	O74	0.58		5,587.86 2.40			409.31 8455.64

JNAUDITED FINANCIAL TS FOR THE ENDED 30 JUNE, 2021

• *s}nsad jeIUBUY Jo JuOUIOWWS S]Y) UO Yodo4 s,Joppne ap Ul VoNBAL;ITENb ou st e104 | popuawe se '¢ | QZ 'suoNEINSoy (squawasmbay ainsoposic] pue uoNPsIGO SuNsi]) [AS oy) JO EE UONLINSoy Jo swusa) ul AuLduUO; axp Jo ssoy|pNy A1oMINIg oY) Aq pomarAas UaAq OSE OALY S)NSAJ 2AOQE ay], "1207 'IsnSny || UO pjoy Funoow sroyp ye sioyasq Jo pavog oy) Aq porosdde pue say!WWUOD pny oy) Aq paMataas a49M 1ZOZ 'ous O¢ Papua soyrenb oy} A0J syNsou jeIoUBUY ay, |
• "aiquorjdde juayxo ay 0} so1syjod pue saoyoesd Supunosoe pasiudooai soyo pue ¢10Z 'Oy sarueduoD ay JO EE] UONDas Jopun paquosaid 'popuoure sv '(Sy Pul) S107 'saimy (sprepuerg SuNUNODSY UEIpUy) sarURdwOD ay) WIM aoURpsOSde UT paredaid UdOq sey JUdTUAIEIS SIL
  • "uonE|NULO jeonnsseULEYd Jo TuyoyseL pue SuLNjoesnueU "Y4waso4 Jo JuaUTas ssoursng a]uIs ul soywsodo AuRdwoo ay] ¢

Z

• *(solueipisqns umop-dojs osye pur) py] Sd BIsepENsnY sjeonnaorUUeYY BAON 'UT BUY suesyIBY| ' pr] (HA) BULLY suUSyIYY AJoLUGU saLTeIpIsqns Jo y[Nso4 jeIOUBULY sopnjott ynsos [eLOUBUL payepI|osUOD ay, p
• "siseq [Buosoyosd UO syuBsEM J9d OO'pZ 'sy JO do1Ad Bye pay] JOA SUNUMEYY AJ PISY PAIGIO 0} suRTEA 21qHIDAUOD pZE'PT'EG'p PUL BYULPTES UPA "IY 0} SHUBITEAL aIqrUDAUOD 9QO'0O'OI PENOTTe pue panssi sey *|ZOz "AIng prgz UO Pjoy Sunsaw sy ye KueduioD oy Jo sioyda.1q Jo pawog ay "| ZO "Ajnye WIG UO Pjay Sunoapy jesousH Arvuypi0-e.nxy oUp 1 siapjoyoueys ay Aq passed uoNnjosay [eloadg ay) 0} JUENSINg ¢
• *sUONIPUOD d1OMIODS ainjry 0} SATUBYo|BLIDeUL Aue JO}UOL 0} INUNUOS []1M dnomD/Auedwo| oy) pue syjnso4 jeloueuy au) Jo peaordde yo yep Yons qe se poyUMNse Ss} YA\ WO JUOJaJJIP aq ABUL G]-PIAOD Jo youd! ay], 'sxOyOaIIq Jo pakog oy) Aq SyNso4 jeIOUBUY aIp Jo [eAoudde Jo ayep arp oydn suondeo quowayeys ejouRUyy \$91 0) UOHB]As UL sjasse Jo AjITIquioAODOI pur soyELUNSO sNO}wA BuIZIPoUY O[IYM UOEUUUOJU! [BUIAXO pue [BULDJU! posopisuod sey dnosH /AuedwOD ay], 9
• "ae9K JUD.UND OU) YIM afqesiedwos way) oyeUt 0} Aressadau JaAsIaYyM 'paljisse[oo4 / podnosSas uaa avy sounBy s,porsad snoiwerg £
• cavak [BIOUBULY JUBADIA OY} JO syUOW ouJU O}dn sandy paysr}qnd poypneun oyp pue wax jerouruy |jny oy} Jo yoodsos ul soindy poypne ay usaMmjoq sandy Surourjeq oy) ome 1ZOT 'Your ISTE Papuo JoyNb op soy sendy oy] g

Wwoo'BULeYydsuesyseUr AANA, requinyy :20e,g W207 "snBny Tr + seq

—

WuvHd SKYSHUYIN 493

1g Areyou9eg Aueduiod sebouew stay WeAeysiey ae a ot UENP: '

£8602000 :NIG Ao}OI.NG Tuseueypy wz uBwWreYyD, a. eyueples E/N AdOO ANE galdiLyao